Earnings summaries and quarterly performance for Praxis Precision Medicines.
Executive leadership at Praxis Precision Medicines.
Board of directors at Praxis Precision Medicines.
Research analysts who have asked questions during Praxis Precision Medicines earnings calls.
Ami Fadia
Needham & Company, LLC
6 questions for PRAX
Also covers: ACAD, ALKS, AVDL +11 more
DT
Douglas Tsao
H.C. Wainwright & Co.
6 questions for PRAX
Also covers: ALKS, APLS, ARGX +21 more
JL
Joon Lee
Truist Securities
6 questions for PRAX
Also covers: ADVM, ALKS, AXSM +15 more
Yatin Suneja
Guggenheim Partners
6 questions for PRAX
Also covers: ACAD, ARGX, AXSM +11 more
FB
François Brisebois
Oppenheimer & Co. Inc.
5 questions for PRAX
Also covers: ACHV, AQST, AVDL +12 more
KY
Kambiz Yazdi
Jefferies
5 questions for PRAX
Also covers: ARQT, EYPT, LQDA
YR
Yasmeen Rahimi
Piper Sandler & Co.
5 questions for PRAX
Also covers: ALT, ARCT, CRNX +12 more
RB
Ritu Baral
TD Cowen
4 questions for PRAX
Also covers: ACAD, ALNY, ATAI +11 more
Brian Skorney
Robert W. Baird & Co.
3 questions for PRAX
Also covers: ABUS, BIIB, CRNX +8 more
DH
David Hoang
Citigroup
3 questions for PRAX
Also covers: ACAD, ALKS, AVDL +8 more
Jay Olson
Oppenheimer & Co. Inc.
3 questions for PRAX
Also covers: ACAD, AMGN, BIIB +23 more
JB
Joel Beatty
Baird
3 questions for PRAX
Also covers: ACAD, ALKS, AMLX +11 more
Andrew Tsai
Jefferies
2 questions for PRAX
Also covers: ARQT, ATAI, ATHA +16 more
AC
Athena Chin
TD Cowen
2 questions for PRAX
Also covers: CMPS
BB
Benjamin Burnett
Stifel, Nicolaus & Company, Incorporated
2 questions for PRAX
Also covers: AXSM, IOVA, PGEN +2 more
JW
Justin Walsh
Jones Trading
2 questions for PRAX
Also covers: ACHV, BLRX, GTBP +7 more
DT
Doug Tsao
H.C. Wainwright & Co.
1 question for PRAX
Also covers: EOLS
LC
Laura Chico
Wedbush Securities
1 question for PRAX
Also covers: APLS, ARDX, BCRX +11 more
RL
Rudy Li
Chardan Capital Markets
1 question for PRAX
Also covers: ACAD, ALKS, MNMD +2 more
YR
Yasmin Rahimi
Piper Sandler
1 question for PRAX
Also covers: PRTA
Recent press releases and 8-K filings for PRAX.
Brainlab and Precision NeuroMed Partner on AI-Driven Brain Drug Delivery Platform
PRAX
New Projects/Investments
M&A
- Brainlab and Precision NeuroMed (PNM) have announced a strategic partnership to develop and commercialize an AI-enabled treatment planning platform for convection enhanced delivery (CED) to the brain.
- The collaboration aims to standardize and scale the delivery of targeted therapies directly into brain tissue, overcoming limitations imposed by the blood-brain barrier.
- The initial development of the CED Treatment Planning System (CED TPS) will focus on supporting PNM’s lead investigational drug, PNM-201, for recurrent glioblastoma.
- As part of the Joint Development and Commercialization Agreement, Brainlab has been granted an equity interest in PNM.
3 days ago
Praxis Precision Medicines Submits Two NDAs and Reports Q4 and Full-Year 2025 Financial Results
PRAX
Earnings
Product Launch
Guidance Update
- Praxis Precision Medicines, Inc. submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for ulixacaltamide in essential tremor (ET) and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). Pre-launch activities for both products are underway and will accelerate through 2026.
- For the fourth quarter of 2025, the company reported a net loss of $88.9 million, with research and development expenses at $77.5 million and general and administrative expenses at $19.5 million.
- For the full year ended December 31, 2025, Praxis reported a net loss of $303.3 million, with research and development expenses totaling $267.1 million and general and administrative expenses at $59.1 million.
- As of December 31, 2025, Praxis had $926.1 million in cash, cash equivalents, and marketable securities. This amount, combined with $621.2 million in net proceeds from a January 2026 public offering, is expected to fund operations into 2028.
- Upcoming clinical milestones include expected topline results in the first half of 2026 for the POWER1 Phase 3 study of vormatrigine for Focal Onset Seizures and the EMBRAVE Part A Phase 1/2 study of elsunersen for early-seizure-onset SCN2A DEE.
Feb 19, 2026, 1:01 PM
Praxis Precision Medicines Submits Two NDAs and Reports Strong Cash Position in Q4 2025
PRAX
Earnings
Product Launch
Guidance Update
- Praxis Precision Medicines submitted two New Drug Applications (NDAs) in early 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A and 8A DEEs.
- The company reported a strong financial position, ending Q4 2025 with $926 million in cash, equivalents, and marketable securities, with pro forma cash of approximately $1.5 billion expected to fund operations into 2028.
- Operating expenses for Q4 2025 totaled $97 million, and full-year 2025 expenses were $326 million, with further significant increases expected in 2026 due to commercial launch preparations.
- Key upcoming catalysts include top-line results for vormatrigine's POWER1 study and elsunersen's EMBRAVE study in the first half of 2026.
Feb 19, 2026, 1:00 PM
Praxis Precision Medicines Reports Q4 2025 Results and Provides Pipeline Updates
PRAX
Earnings
Product Launch
Guidance Update
- Praxis Precision Medicines submitted two New Drug Applications (NDAs) in early 2026: one for ulixacaltamide in essential tremor and another for relutrigine in SCN2A and SCN8A DEEs, following a year of significant clinical achievements and regulatory events in 2025.
- The company estimates ulixacaltamide has a peak annual revenue potential of over $10 billion, while relutrigine could reach $5 billion annually in the full DEE space, and vormatrigine and elsunersen have potential annual revenues of over $4 billion and over $1 billion, respectively.
- Praxis ended Q4 2025 with $926 million in cash, equivalents, and marketable securities, which increased to a pro forma approximately $1.5 billion with a January 2026 public offering, expected to fund operations into 2028.
- Operating expenses for Q4 2025 totaled $97 million, with full-year 2025 operating expenses at $326 million, driven by increased investment in pipeline progression and anticipated significant increases in 2026 for commercial launch activities.
- The company requested priority review for the relutrigine NDA but not for the ulixacaltamide NDA, citing broader business reasons for the latter, including maximizing revenue over time and considering the Inflation Reduction Act.
Feb 19, 2026, 1:00 PM
Praxis Precision Medicines Reports Q4 2025 Results, Submits Two NDAs, and Highlights Strong Pipeline Progress
PRAX
Earnings
Product Launch
Guidance Update
- Praxis Precision Medicines reported Q4 2025 operating expenses of $97 million and full-year 2025 operating expenses of $326 million.
- The company ended Q4 2025 with $926 million in cash, equivalents, and marketable securities, which was further strengthened by $621 million from a January 2026 public offering, resulting in a pro forma cash position of approximately $1.5 billion expected to fund operations into 2028.
- Praxis submitted two New Drug Applications (NDAs): one for ulixacaltamide in essential tremor and one for relutrigine in SCN2A and SCN8A DEEs. Ulixacaltamide has a peak potential of over $10 billion annually, and relutrigine has a full potential of up to $5 billion in annual revenue.
- Key clinical readouts expected in 2026 include top-line results for vormatrigine in focal epilepsy (POWER1 study in Q2) and elsunersen in EMBRAVE data (H1), with vormatrigine having a potential for over $4 billion in annual revenue and elsunersen for over $1 billion annually.
Feb 19, 2026, 1:00 PM
Praxis Precision Medicines Reports Q4 and Full-Year 2025 Financial Results and Provides Corporate Update
PRAX
Earnings
Product Launch
Guidance Update
- Praxis Precision Medicines reported $926.1 million in cash, cash equivalents and marketable securities as of December 31, 2025, and expects to fund operations into 2028 with an additional $621.2 million from a January 2026 public offering.
- The company submitted two New Drug Applications (NDAs) to the FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs).
- For the fourth quarter of 2025, Praxis incurred a net loss of $88.9 million, and a net loss of $303.3 million for the full year 2025.
- Pre-launch activities for ulixacaltamide and relutrigine are accelerating through 2026, with the CEO stating that four assets have a revenue potential of over $20 billion.
Feb 19, 2026, 12:30 PM
Praxis Precision Medicines Provides Updates on NDA Filings, Clinical Programs, and Financial Position
PRAX
Product Launch
Guidance Update
New Projects/Investments
- Praxis Precision Medicines is on track to file two New Drug Applications (NDAs) around mid-February 2026 for ulixacaltamide hydrochloride (for essential tremor) and relutrigine (for SCN2A and SCN8A).
- For ulixacaltamide hydrochloride, the company estimates a pricing sweet spot of $40,000-$60,000 per year, with the CEO projecting peak sales of $10 billion-$15 billion+.
- The EMERALD study for relutrigine (targeting a broader DEE population) is expected to read out in the second half of 2026, with potential for accelerated sNDA approval via the STAR program if positive.
- The POWER1 study for vormatrigine (for focal onset seizures) is anticipated to read out in the first half of 2026, representing another potential multi-billion dollar opportunity.
- The company reports a cash position of approximately $1.5 billion, providing a runway into 2028 and likely to break even, and expects to be eligible for two Priority Review Vouchers.
Feb 11, 2026, 6:00 PM
Praxis Precision Medicines Discusses Upcoming NDAs, Pipeline, and Financial Position
PRAX
Product Launch
New Projects/Investments
Guidance Update
- Praxis Precision Medicines is on track to file two New Drug Applications (NDAs) around mid-February 2026 for ulixacaltamide hydrochloride (for essential tremor) and relutrigine (for SCN2A and SCN8A).
- Ulixacaltamide hydrochloride targets a significant essential tremor market, with 1-2 million patients actively seeking treatment in the U.S., and has a potential annual pricing "sweet spot" of $40,000-$60,000.
- The EMERALD study for relutrigine, targeting a broader DEE population, is expected to finalize and read out in the second half of 2026, with potential for accelerated approval through the STAR program.
- The company maintains a strong financial position with approximately $1.5 billion in cash, providing a runway into 2028 and likely to reach break-even, and anticipates receiving two priority review vouchers.
Feb 11, 2026, 6:00 PM
Praxis Precision Medicines Provides Pipeline and Financial Updates at Biotech Summit
PRAX
Product Launch
New Projects/Investments
Guidance Update
- Praxis Precision Medicines is on track to file two New Drug Applications (NDAs) for ulixacaltamide hydrochloride (essential tremor) and relutrigine (SCN2A and SCN8A) around mid-February 2026.
- The company projects ulixacaltamide hydrochloride to have potential peak sales of $10 billion-$15 billion+, with an estimated annual price in the $40,000-$60,000 range.
- The EMERALD study for relutrigine, which could significantly expand its market to a broader Dravet Syndrome (DEE) population, is expected to finalize and read out in 2H 2026, potentially leading to an accelerated sNDA approval in early 2027.
- Praxis maintains a strong cash position of approximately $1.5 billion, providing a runway into 2028, and anticipates results from the POWER1 study for vormatrigine (focal onset seizures) in 1H 2026.
Feb 11, 2026, 6:00 PM
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy
PRAX
Management Change
Hiring
New Projects/Investments
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the appointment of Dr. Orrin Devinsky, M.D., as its new Head of Clinical Strategy on January 13, 2026.
- Dr. Devinsky is a world-renowned neurologist and epilepsy authority with over four decades of experience, having shaped the development of multiple transformative therapies and served as Principal Investigator for pivotal clinical trials leading to the first FDA approval of cannabidiol therapy for rare epilepsies.
- In this new leadership role, Dr. Devinsky will guide clinical strategy and global medical affairs, focusing on program architecture, evidence generation, and external scientific engagement as Praxis advances its growing late-stage portfolio toward commercialization.
Jan 13, 2026, 9:30 PM
Quarterly earnings call transcripts for Praxis Precision Medicines.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more